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Abstract The purposes of the study were to estimate the incidence of metabolic syndrome (MetS) and to systematically
evaluate the relationship between hematological parameters and MetS in a 5-year follow-up of Beijing adult
population. The longitudinal study included 3,180 adults, aged 20–65 years, who attended health check-ups
in Beijing Tongren Hospital in 2007 and 2012. Multivariate logistic regression was conducted to explore the
associations between hematological parameters and MetS. The 5-year cumulative incidence of MetS in this
sample was 10.82 % (14.22 % for males and 7.59 % for females). Among all the hematological parameters,
white blood cell count (WBC) was positively associated with MetS for 20–35-year-old (male OR 1.482, 95 %
CI 1.169–2.974; female OR 1.398, 95 % CI 1.145–3.011), and 36–50-year-old (male OR 2.012, 95 % CI
1.290–4.010; female OR 3.400, 95 % CI 1.818–4.528) male and female subjects. Alanine aminotransferase
(ALT) was significantly associated with the incidence of MetS for males (20–35-year-old OR 2.080, 95 %
CI 1.371–3.159; 36–50-year-old OR 2.421, 95 % CI 1.335–3.412; 51–65-year-old OR 4.267, 95 % CI 1.161–
6.781). Low-density lipoprotein cholesterol (LDL-C) was positively associated with MetS for 51–65-year-
old (male OR 3.078, 95 % CI 2.468–5.131; female OR 2.140, 95 % CI 1.524–4.359) for male and female
subjects. WBC is positively associated with MetS for young adults, while LDL-C is positively associated
with MetS for elderly people. ALT is positively associated with MetS for males. Our findings provide further
evidence in support of using hematological markers for early detection of individuals at risk for MetS.
Keywords (separated by '-') Hematological parameters - Metabolic syndrome - Association - Longitudinal study
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9 Abstract The purposes of the study were to estimate the
10 incidence of metabolic syndrome (MetS) and to systemati-
11 cally evaluate the relationship between hematological
12 parameters and MetS in a 5-year follow-up of Beijing adult
13 population. The longitudinal study included 3,180 adults,
14 aged 20–65 years, who attended health check-ups in Beijing
15 Tongren Hospital in 2007 and 2012. Multivariate logistic
16 regression was conducted to explore the associations between
17 hematological parameters and MetS. The 5-year cumulative
18 incidence of MetS in this sample was 10.82 % (14.22 % for
19 males and 7.59 % for females). Among all the hematological
20 parameters, white blood cell count (WBC) was positively
21associated with MetS for 20–35-year-old (male OR 1.482,
2295 % CI 1.169–2.974; female OR 1.398, 95 % CI
231.145–3.011), and 36–50-year-old (male OR 2.012, 95 % CI
241.290–4.010; female OR 3.400, 95 % CI 1.818–4.528) male
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33subjects. WBC is positively associated with MetS for young
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36males. Our findings provide further evidence in support of
37using hematologicalmarkers for early detection of individuals
38at risk for MetS.
39
40Keywords Hematological parameters  Metabolic
41syndrome  Association  Longitudinal study
42Introduction
43Metabolic syndrome (MetS) is a cluster of risk factors that
44include abdominal obesity, hyperglycemia, raised blood
45pressure (BP), low high-density lipoprotein cholesterol
46(HDL-C), and high triglycerides (TG). Since prevalence of
47MetS is rapidly growing and it is associated with an
48increased risk of insulin resistance, diabetes, cardiovascu-
49lar disease (CVD), and total mortality [1–3], the identifi-
50cation for biomarkers of MetS is of pivotal importance.
51The prevalence of MetS increased with age for both
52sexes [4]. Several non-inflammatory biomarkers have been
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53 associated with MetS and its components in different
54 populations, including growth factors [5], micro albumin-
55 uria [6], and uric acid (UA) [7, 8]. Elevated white blood
56 cell (WBC) count is intimately linked to the prevalence and
57 future development of MetS in populations of working
58 subjects [9, 10]. Insulin resistance and/or hyperinsulinemia
59 have been shown to correlate with WBC counts [11].
60 Elevated liver enzymes, especially alanine aminotransfer-
61 ase (ALT) may be related with and a better predictor for
62 MetS [12–14]. Other hematological parameters including
63 platelet counts (PLT), hemoglobin (HGB), hematocrit
64 concentrations (HCT), C-reactive protein, and serum bili-
65 rubin increased with increasing numbers of MetS compo-
66 nents [15–18]. To the best of our knowledge, there have
67 been few studies conducting systematic evaluation for
68 relationship between hematological parameters and MetS
69 for different age groups of males and females in a large
70 Beijing adult population.
71 Therefore, the aims of this study were to estimate the
72 incidence of MetS and to investigate prospective associa-
73 tions between blood parameters and MetS in a Beijing
74 adult population.
75 Materials and methods
76 Subjects
77 A total of 3,832 subjects aged 20–65 years who attended
78 health check-ups in Beijing Tongren Hospital, China, in
79 2007 and 2012 were enrolled in the study. Individuals with
80 a previous diagnosis of CVD, cerebral infarction or gastric
81 cancer, or those who had undergone coronary artery bypass
82 surgery, coronary stenting surgery or gastrectomy, or those
83 who had MetS at baseline were excluded. The remaining
84 3,180 subjects were included in the final analysis. The
85 study was approved by the Ethics Committee of Capital
86 Medical University (approval number: 2013SY26). Written
87 informed consent was obtained from all the participating
88 subjects.
89 Measurements
90 Information about medication use was gathered by trained
91 medical staff during a standardized interview. Subjects
92 who reported taking anti-hypertensive, anti-dyslipidemic,
93 or anti-diabetic drugs were considered to have elevated BP,
94 elevated TG, reduced HDL-C, or elevated fasting plasma
95 glucose (FPG).
96 The participants underwent routine physical examina-
97 tions that included the measurement of height, weight, BP,
98 and overnight fasting blood sampling. Weight and height
99 were measured without shoes, and body mass index (BMI)
100was calculated as weight (kg) divided by squared height
101(m). BP was measured on the right arm of subjects seated
102and at rest for at least 5 min by a trained nurse. During the
10330 min preceding the measurements, the subjects were
104required to refrain from smoking or consuming caffeine. A
105standard mercury sphygmomanometer was used with one
106of four cuff sizes (pediatric, regular adult, large adult, or
107thigh) based on the participant’s arm circumference. Three
108readings each of systolic and diastolic BPs were recorded,
109with an interval of 1 min at least, and the average of the
110last two measurements was used for data analysis.
111Blood samples were obtained from antecubital vein into
112tubes containing EDTA in the morning after an overnight
113fasting period. Red blood cell (RBC), WBC, lymphocyte,
114neutrophil, mean corpuscular hemoglobin (MCH), PLT,
115mean platelet volume (MPV), platelet distribution width
116(PDW), and HGB were measured by an autoanalyzer
117(Sysmex SE-9000, Kobe, Japan). HDL-C, TG, FPG, ALT,
118aspartate aminotransferase (AST), UA, and LDL-C were
119measured by enzymatic method using a chemistry analyzer
120(Beckman LX 20, USA) at the central laboratory of the
121hospital. All analyses were performed in accordance with
122the manufacturer’s recommendations.
123Definitions
124MetS was diagnosed if the subjects had three or more risk
125determinants according to the Joint Interim Statement cri-
126teria [19]. However, in this study, waist circumference
127(WC) was not measured because of limited health check-up
128site, and BMI was taken as a substitute for the component
129of obesity [20]. The determinants were as follows:
130(1) Obesity: BMI C 28 kg/m
2. (2) Elevated TG (drug
131treatment for elevated TG is an alternate indicator):
132C150 mg/dL (1.7 mmol/L). (3) Reduced HDL-C (drug
133treatment for reduced HDL-C is an alternate indicator):
134\40 mg/dL (1.0 mmol/L) in males,\50 mg/dL (1.3 mmol/
135L) in females. (4) Elevated BP (antihypertensive drug
136treatment in a patient with a history of hypertension is an
137alternate indicator): systolic C130 mmHg and/or diastolic
138C85 mmHg, and (5) Elevated FPG (drug treatment of ele-
139vated glucose is an alternate indicator): C100 mg/dL.
140Statistical analysis
141Data were expressed as mean ± standard deviation (SD)
142or, for non-normally distributed variables, as median and
143interquartile range. To compare the differences between
144groups, student’s t test or Wilcoxon rank sum test was used
145for continuous variables, and v
2 test or Fisher’s exact test
146was used for categorical variables. Log transformations
147were applied to skewed data prior to parametric analyses.
148Multiple logistic regression analysis was used to assess the
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149 relationship between hematological parameters and MetS
150 after adjusting for medication use. Data were analysed
151 using the SAS software package (version 9.2; SAS Insti-
152 tute, Chicago, IL, USA), and P\ 0.05 was considered
153 significant.
154 Results
155 The incidence of MetS and prevalence of its
156 components by age and gender
157 The sample of this study represents 3,180 subjects,
158 including 1,547 males and 1,633 females aged 20–65 years
159 old. The sex- and age-specific incidence of MetS, preva-
160 lence of its components, and medical use are shown in
161 Table 1 and Figs. 1 and 2.
162 Overall, the 5-year cumulative incidence of MetS
163 among all subjects was 10.82 %, with 14.22 % of males
164 and 7.59 % of females having MetS. Of note, the 5-year
165 cumulative incidence of MetS among 36–50-year-old male
166 subjects was the highest (15.40 %). And the 20–35-year-
167 old female subjects had the lowest incidence (4.13 %).
168 While among female subjects, the 51–65-year-old subjects
169had the highest 5-year cumulative incidence of MetS
170(14.05 %).
171The prevalence of MetS components is shown in Fig. 2.
172The prevalence of elevated BP and elevated FPG increased
173with age for male subjects, while the prevalence decreased
174with age for reduced HDL-C and elevated BMI for male
175subjects. The highest prevalence of elevated TG was pre-
176sented in 36–50-year-old group among males. For female
Table 1 The incidence of MetS, prevalence of its components and medication use
Gender Variables Age at inclusion (years) P value
20–35 36–50 51–65
Male N 681 591 275
MetS, n (%) 94 (13.80) 91 (15.40) 35 (12.73) 0.5296
Elevated BP, n (%) 190 (27.90) 202 (34.18) 118 (42.91) \0.0001
Elevated TG, n (%) 216 (31.72) 208 (35.19) 75 (27.27) 0.0623
Reduced HDL-C, n (%) 170 (27.96) 111 (18.78) 42 (15.27) 0.0011
Elevated BMI, n (%) 104 (15.27) 75 (12.69) 27 (9.82) 0.0682
Elevated FPG, n (%) 62 (18.36) 203 (35.36) 87 (46.55) \0.0001
Anti-hypertensive drugs, n (%) 5 (0.73) 70 (11.81) 51 (18.55) \0.0001
Anti-dyslipidemic drugs, n (%) 41 (6.02) 82 (13.87) 37 (13.45) \0.0001
Anti-diabetic drugs, n (%) 31 (4.55) 74 (12.61) 37 (13.45) \0.0001
Female N 533 858 242
MetS, n (%) 22 (4.13) 68 (7.93) 34 (14.05) 0.0023
Elevated BP, n (%) 42 (7.88) 151 (17.60) 78 (32.23) \0.0001
Elevated TG, n (%) 41 (7.69) 144 (16.78) 52 (21.49) \0.0001
Reduced HDL-C, n (%) 140 (26.27) 211 (24.59) 56 (23.14) 0.6141
Elevated BMI, n (%) 17 (3.19) 52 (6.06) 16 (6.61) 0.0363
Elevated FPG, n (%) 125 (11.63) 209 (23.66) 128 (35.97) \0.0001
Anti-hypertensive drugs, n (%) 6 (1.13) 50 (5.83) 47 (19.42) \0.0001
Anti-dyslipidemic drugs, n (%) 2 (0.38) 11 (1.28) 15 (6.20) \0.0001
Anti-diabetic drugs, n (%) 16 (3.00) 38 (4.43) 28 (11.57) \0.0001
MetS metabolic syndrome, BP blood pressure, TG triglycerides, HDL-C high-density lipoprotein cholesterol, BMI body mass index, FPG fasting
plasma glucose
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177 subjects, the prevalence of elevated BP, elevated TG, ele-
178 vated BMI, and elevated FPG increased with age, whereas
179 the descending trend was presented in the prevalence of
180 reduced HDL-C. Male subjects had higher prevalence of
181 elevated BP, elevated TG, elevated BMI, and elevated FPG
182 levels than female subjects, whereas female subjects had a
183 higher prevalence of reduced HDL-C level for all age
184 groups than male subjects.
185 Basic characteristics and hematological parameters
186 of subjects by age and gender
187 The basic characteristics and hematological parameters of
188 20–35-year-old subjects are displayed in Table 2. Besides
189 the five MetS components, significant difference was found
190 in ALT, AST, UA, WBC, lymphocytes, neutrophils, HGB,
191 LDL-C levels, and the prevalence of taking anti-dyslipi-
192 demic drugs between MetS and non-MetS group for males.
193 As for female subjects, significant difference was observed
194 between the MetS group and non-MetS group for BMI,
195 HDL-C, TG, FPG, SBP, ALT, AST, and LDL-C levels.
196 The basic characteristics and hematological parameters
197 for 36–50-year-old subjects are presented in Table 3.
198 Significant difference was found in BMI, HDL-C, TG,
199 FPG, ALT, AST, UA, RBC, WBC, lymphocyte, neutro-
200 phil, HGB, LDL-C levels, and the prevalence of taking
201 anti-dyslipidemic drugs between MetS and non-MetS
202 group for males. While for females, significant difference
203 was found in BMI, HDL-C, TG, FPG, SBP, DBP, ALT,
204 UA, RBC, WBC, lymphocyte, neutrophil, PLT, MPV,
205 HGB, and LDL-C levels between MetS and non-MetS
206 group.
207 The basic characteristics and hematological parameters
208 for 51–65-year-old subjects are shown in Table 4. Signif-
209 icant difference was found in BMI, HDL-C, TG, UA, and
210 LDL-C levels between MetS and non-MetS group for
211 males. As for females, significant difference was found in
212BMI, HDL-C, TG, FPG, UA, HGB, and LDL-C levels
213between MetS and non-MetS group.
214Associated risk factors for MetS by age and gender
215Logistic regression analysis was used to determine asso-
216ciations between blood parameters and incidence of MetS
217after adjusted for the presence of anti-hypertensive, anti-
218dyslipidemic, and anti-diabetic medication use (Table 5;
219Fig. 3).
220For 20–35-year-old subjects, hematological parameters
221positively associated with MetS were ALT (OR 2.080,
22295 % CI 1.371–3.159), UA (OR 2.135, 95 % CI
2231.294–3.614), and WBC (OR 1.482, 95 % CI 1.169–2.974)
224for males. While neutrophils (OR 1.059, 95 % CI
2251.023–1.453), WBC (OR 1.398, 95 % CI 1.145–3.011),
226and UA (OR 1.523, 95 % CI 1.040–3.147) were positively
227associated with MetS for females.
228As for 36–50-year-old subjects, ALT (OR 2.421, 95 % CI
2291.335–3.412), WBC (OR 2.012, 95 % CI 1.290–4.010), and
230HGB (OR 1.045, 95 % CI 1.018–2.020) were positively
231associatedwithMetS formales.WhileWBC(OR 3.400, 95 %
232CI 1.818–4.528), and PLT (OR 2.616, 95 % CI 1.432–3.033)
233were positively associated with MetS for females.
234Hematological parameters associated with MetS for
23551–65-year-old male subjects were ALT (OR 4.267, 95 %
236CI 1.161–6.781) and LDL-C (OR 3.078, 95 % CI
2372.468–5.131). However, UA (OR 1.025, 95 % CI
2381.011–1.321), HGB (OR 1.256, 95 % CI 1.145–3.105), and
239LDL-C (OR 2.140, 95 % CI 1.524–4.359) were positively
240associated with MetS for 51–65-year-old females.
241Discussion
242The study investigated the cumulative incidence of MetS
243and systematically evaluated the prospective associations
0
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244 between several common hematological parameters and
245 MetS by age and gender in a Beijing adult population.
246 The overall prevalence of MetS ranges from 6 to 38 %
247 of the general population in the United States, Europe and
248 Asia, including Korea [21–23]. A cohort study conducted
249 in a Taiwanese health-screening population aged
250 35–74 years showed that the 5-year cumulative incidence
251 of MetS was 11.37, 14.95 % for males and 9.89 % for
252 females [24]. In our study, the 5-year cumulative incidence
253of MetS among all subjects was 10.82 %, with 14.22 % of
254males and 7.59 % of females having MetS after 5-year
255follow-up.
256Previous cross-sectional studies found that sex and age
257were associated with prevalence of MetS [25, 26]. It is well
258established that the prevalence of MetS rises from young to
259old ages [27, 28]. Compared with males, females had a
260significantly higher prevalence of central obesity and
261reduced HDL-C, whereas males had a significantly higher
Table 2 Basic characteristics and hematological parameters of 20–35-year-old subjects
Variables Male (N = 681) Female (N = 533)
MetS Non-MetS P value MetS Non-MetS P value
N 94 587 – 22 511 –
BMI (kg/m2) 26.56 ± 2.84 23.76 ± 3.13 \0.0001a 24.99 ± 3.22 20.87 ± 2.64 \0.0001a
HDL-C (mmol/L) 1.17 ± 0.23 1.32 ± 0.27 \0.0001a 1.32 (1.16–1.47) 1.60 (1.40–1.82) \0.0001b
TG (mmol/L) 1.49 (1.13–2.32) 1.04 (0.72–1.59) \0.0001b 1.01 (0.55–1.59) 0.67 (0.49–0.91) 0.0065b
FPG (mmol/L) 5.30 (4.97–5.49) 5.06 (4.80–5.33) 0.0003b 5.41 (4.85–5.49) 4.99 (4.74–5.24) 0.0002b
SBP (mmHg) 120 (110–130) 115 (110–120) 0.0007b 110 (100–120) 100 (100–110) 0.0116b
DBP (mmHg) 80 (70–90) 75 (70–80) \0.0001b 70 (70–80) 70 (60–75) 0.1419b
ALT (U/L) 29.00 (22.00–49.00) 22.00 (17.00–33.00) \0.0001b 16.00 (15.00–20.00) 14.00 (11.00–17.00) 0.0101b
AST (U/L) 31.00 (27.00–38.00) 28.00 (25.00–33.00) 0.0014b 29.00 (24.00–32.00) 26.00 (23.00–29.00) 0.0387b
UA (lmol/L) 390.00
(353.00–421.00)
355.00
(320.00–396.00)
\0.0001b 252.00
(236.00–312.00)
254.00
(220.00–282.00)
0.4441b
RBC (91012/L) 5.22 ± 0.30 5.15 ± 0.34 0.0626a 4.45 ± 0.32 4.44 ± 0.29 0.5051a
WBC (9109/L) 6.90 (5.87–7.90) 6.20 (5.40–7.20) 0.0006b 6.30 (4.92–7.50) 5.80 (5.02–6.70) 0.1887b
Lymphocyte (9 109/
L)
2.45 ± 0.64 2.26 ± 0.58 0.0054a 2.06 ± 0.39 2.11 ± 0.52 0.6173a
Neutrophil (9109/L) 3.90 (3.40–4.60) 3.47 (2.87–4.20) 0.0012b 3.95 (2.80–4.70) 3.39 (2.78–4.00) 0.0516b
MCH (pg) 29.80 (29.30–30.80) 30.10 (29.20–30.80) 0.5710b 29.75 (28.40–31.60) 29.80 (28.90–30.70) 0.7727b
PLT (9109/L) 228.85 ± 50.99 220.37 ± 47.48 0.1140a 248.60 ± 54.79 227.36 ± 49.89 0.0522a
MPV (fl) 9.88 ± 0.91 9.80 ± 1.00 0.3984a 9.75 ± 0.85 9.81 ± 1.01 0.7700a
PDW (%) 11.60 (10.90–12.90) 11.70 (10.70–12.90) 0.4810b 11.65 (11.10–13.00) 11.80 (10.80–12.90) 0.7978b
HGB (g/L) 156.00 ± 7.60 154.15 ± 8.99 0.0348a 134.50
(132.00–138.00)
131.00
(126.00–137.00)
0.1098b
LDL-C (mmol/L) 3.12 ± 0.63 2.85 ± 0.70 0.0006a 2.91 (2.71–3.10) 2.46 (2.12–2.88) 0.0002b
Anti-hypertensive
drugs
n (%) 2 (2.13) 3 (0.51) 0.1426d 1 (4.55) 5 (0.98) 0.2244d
Anti-dyslipidemic
drugs
n (%) 11 (11.70) 30 (5.11) 0.0126c 1 (4.55) 1 (0.98) 0.0809c
Anti-diabetic drugs
n (%) 5 (5.32) 26 (4.43) 0.6026d 2 (9.09) 14 (2.74) 0.1376d
SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST aspartate aminotransferase, UA uric acid, RBC red
blood cell count, WBC white blood cell count, MCH mean corpuscular hemoglobin, PLT platelet count, MPV mean platelet volume, PDW
platelet distribution width, HGB hemoglobin, LDL-C low-density lipoprotein cholesterol
a The result of student’s t test
b The result of Wilcoxon rank sum test
c The result of v2 test
d The result of Fisher’s exact test
Endocrine
123
Journal : Large 12020 Dispatch : 19-9-2013 Pages : 11
Article No. : 67
h LE h TYPESET
MS Code : ENDO-D-13-00417 h CP h DISK4 4
A
u
th
o
r
 P
r
o
o
f
U
N
C
O
R
R
E
C
T
E
D
P
R
O
O
F
262 prevalence of raised BP compared with females [29]. Our
263 results are roughly consistent with these observations. In
264 this study, the incidence of MetS increased with age for
265 females, while the same trend was not found for males. The
266 prevalence of elevated BP and FPG increased with age for
267 male subjects, and the prevalence of elevated BP, TG,
268 BMI, and FPG increased with age for female subjects,
269 whereas the descending trend was presented in the preva-
270 lence of reduced HDL-C for female subjects. Information
271from our study suggests that males are more prone to be
272affected by MetS compared to females for young and
273middle-age people, while females are at higher risk for
274MetS for elderly people. The incidence of MetS and
275prevalence of its components in this population underlines
276the need to screen for associated hematological factors for
277MetS.
278Several reports have demonstrated that altered hemato-
279logical status in patients is a high risk factor for MetS.
Table 3 Basic characteristics and hematological parameters of 36–50-year-old subjects
Variables Male (N = 591) Female (N = 858)
MetS Non-MetS P value MetS Non-MetS P value
N 91 500 – 68 790 –
BMI (kg/m2) 26.44 ± 2.16 24.18 ± 2.54 \0.0001a 25.64 ± 3.07 22.57 ± 2.62 \0.0001a
HDL-C (mmol/L) 1.14 (1.06–1.33) 1.32 (1.15–1.52) \0.0001b 1.36 ± 0.23 1.66 ± 0.34 0.0257a
TG (mmol/L) 1.83 (1.41–2.83) 1.20 (0.87–1.73) \0.0001b 1.23 (1.02–1.65) 0.86 (0.64–1.20) \0.0001b
FPG (mmol/L) 5.53 (5.26–5.90) 5.32 (5.03–5.61) 0.0061b 5.39 (5.11–5.78) 5.18 (4.90–5.47) \0.0001b
SBP (mmHg) 120 (110–125) 113 (105–120) 0.1598b 120 (108–125) 110 (100–120) \0.0001b
DBP (mmHg) 80 (70–85) 80 (70–85) 0.2980b 80 (70–80) 70 (70–80) \0.0001b
ALT (U/L) 29.00 (22.00–39.00) 22.00 (18.00–31.00) \0.0001b 17.00 (14.00–22.00) 15.00 (12.00–20.00) 0.0117b
AST (U/L) 33.00 (29.00–39.00) 30.00 (26.00–34.00) 0.0015b 28.00 (25.00–31.00) 27.00 (24.00–30.00) 0.2298b
UA (lmol/L) 355.00
(324.00–399.00)
338.00
(301.00–377.00)
0.0007b 275.50
(243.50–305.50)
244.00
(213.00–280.00)
0.0002b
RBC (91012/L) 5.14 ± 0.31 5.03 ± 0.34 0.0026a 4.56 ± 0.28 4.39 ± 0.32 \0.0001a
WBC (9109/L) 6.80 (5.80–8.03) 6.10 (5.25–7.30) \0.0001b 6.45 (5.70–7.70) 5.70 (4.90–6.60) \0.0001b
Lymphocyte (9109/
L)
2.30 (2.00–2.70) 2.10 (1.70–2.50) 0.0043b 2.17 (1.90–2.50) 1.90 (1.60–2.20) \0.0001b
Neutrophil (9109/L) 4.10 (3.40–5.00) 3.50 (2.90–4.30) \0.0001b 3.90 (3.45–4.62) 3.40 (2.76–4.10) \0.0001b
MCH (pg) 30.53 ± 1.45 30.42 ± 1.79 0.5371a 29.60 (28.65–30.90) 30.10 (29.10–30.90) 0.2029b
PLT (9109/L) 214.10 ± 46.17 213.06 ± 46.11 0.8438a 262.30 ± 60.03 228.68 ± 50.00 \0.0001a
MPV (fl) 9.40 (8.90–10.10) 9.40 (8.70–10.10) 0.4320b 9.20 (8.65–10.00) 9.50 (8.90–10.20) 0.0265b
PDW (%) 11.50 (10.80–12.80) 11.40 (10.30–12.70) 0.3026b 11.15 (10.40–12.00) 11.60 (10.60–12.80) 0.0501b
HGB (g/L) 156.80 ± 9.43 152.47 ± 8.76 \0.0001a 136.00
(130.00–139.00)
131.00
(125.00–137.00)
0.0009b
LDL-C (mmol/L) 3.29 ± 0.78 3.10 ± 0.72 0.0249a 3.07 (2.63–3.32) 2.77 (2.42–3.31) 0.0119b
Anti-hypertensive
drugs
n (%) 15 (16.48) 55 (11.00) 0.1365c 7 (10.29) 43 (5.44) 0.1059d
Anti-dyslipidemic
drugs
n (%) 19 (20.88) 63 (12.60) 0.0356c 1 (1.47) 10 (1.27) 0.5990d
Anti-diabetic drugs
n (%) 17 (18.68) 57 (11.40) 0.0536c 6 (8.82) 32 (4.05) 0.1125d
SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST aspartate aminotransferase, UA uric acid, RBC red
blood cell count, WBC white blood cell count, MCH mean corpuscular hemoglobin, PLT platelet count, MPV mean platelet volume, PDW
platelet distribution width, HGB hemoglobin, LDL-C low-density lipoprotein cholesterol
a The result of student’s t test
b The result of Wilcoxon rank sum test
c The result of v2 test
d The result of Fisher’s exact test
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280 Elevated ALT was found to be predictive of MetS among
281 adolescents and young adults in mainland China [30]. The
282 prevalence of MetS increases with the increase in blood
283 levels of ALT even through the normal range of ALT in
284 Japanese men and women [31]. Our results showed that
285 ALT was significantly associated with the incidence of
286 MetS only for males. The result indicated that the associ-
287 ation between ALT and MetS was gender-specific.
288 There are significant associations among UA, CVD, and
289 MetS [32, 33], partly explained by the activation of the
290renin–angiotensin system by obesity [34] or vascular dys-
291function including inflammation. In addition, nutritional
292factors are speculated to affect the occurrence of MetS and
293also of UA. Significant association between UA and MetS
294was found in 20–35-year-old males and females, and
29551–65-year-old females.
296Jesri et al. [35] reported that subjects with MetS had
297higher PLT and WBC counts than controls, and these two
298parameters linearly increased as the number of MetS
299components increased. WBC was associated with MetS
Table 4 Basic characteristics and hematological parameters of 51–65-year-old subjects
Variables Male (N = 275) Female (N = 242)
MetS Non-MetS P value MetS Non-MetS P value
N 35 240 – 34 208 –
BMI (kg/m2) 26.36 ± 2.63 24.50 ± 2.85 0.0009a 25.97 ± 2.95 23.32 ± 2.59 \0.0001a
HDL-C (mmol/L) 1.18 (1.09–1.29) 1.30 (1.13–1.51) 0.0070b 1.42 ± 0.30 1.69 ± 0.34 \0.0001a
TG (mmol/L) 1.89 (1.28–3.43) 1.24 (0.87–1.65) \0.0001b 1.58 (1.30–1.85) 1.10 (0.78–1.55) \0.0001b
FPG (mmol/L) 5.47 (4.97–6.04) 5.44 (5.11–5.83) 0.8788b 5.57 (5.22–6.06) 5.37 (5.00–5.77) 0.0428b
SBP (mmHg) 120 (110–125) 120 (105–125) 0.2890b 120 (110–130) 120 (105–125) 0.2501b
DBP (mmHg) 75 (70–85) 80 (70–85) 1.0000b 80 (70–85) 80 (70–80) 0.4339b
ALT (U/L) 21.50 (18.00–31.00) 20.00 (17.00–28.00) 0.2591b 20.00 (15.00–29.00) 18.00 (14.00–23.00) 0.1268b
AST (U/L) 27.50 (25.00–33.00) 29.00 (26.00–35.00) 0.2247b 28.50 (25.00–32.00) 29.00 (26.00–33.00) 0.6593b
UA (lmol/L) 364.30 ± 65.78 340.21 ± 66.90 0.0471a 295.20 ± 51.90 270.30 ± 58.50 0.0204a
RBC (91012/L) 5.00 (4.79–5.21) 4.88 (4.65–5.12) 0.1854b 4.41 (4.34–4.76) 4.42 (4.21–4.61) 0.1263b
WBC (9109/L) 7.13 (5.90–7.72) 6.30 (5.30–7.40) 0.0830b 6.09 (5.00–6.71) 5.53 (4.80–6.68) 0.2791b
Lymphocyte (9109/
L)
2.40 (1.73–2.70) 2.10 (1.70–2.60) 0.2712b 2.15 (1.90–2.60) 2.00 (1.69–2.40) 0.1411b
Neutrophil (9109/L) 4.20 (3.20–4.80) 3.60 (3.00–4.56) 0.1119b 3.15 (2.63–4.01) 3.20 (2.50–3.90) 0.5432b
MCH (pg) 31.00 (29.80–31.40) 30.80 (29.90–31.80) 0.6847b 30.05 (29.30–31.10) 29.95 (29.10–30.90) 0.4624b
PLT (9109/L) 196.00
(175.00–239.00)
205.00
(180.00–242.00)
0.9187b 214.00
(185.00–249.00)
218.00
(189.00–256.00)
0.7302b
MPV (fl) 9.30 (8.80–9.80) 9.30 (8.60–9.90) 0.8346b 9.55 (8.80–10.30) 9.40 (8.90–10.10) 0.7320b
PDW (%) 11.40 (10.40–12.40) 11.30 (10.30–12.30) 0.7369b 11.25 (10.70–12.40) 11.55 (10.60–12.40) 0.9842b
HGB (g/L) 152.60 ± 8.94 151.30 ± 8.87 0.4173a 135.90 ± 8.65 131.39 ± 9.25 0.0091a
LDL-C (mmol/L) 3.46 ± 0.86 3.16 ± 0.70 0.0266a 3.67 (3.38–4.31) 3.43 (2.86–3.90) 0.0227b
Anti-hypertensive
drugs
n (%) 9 (25.71) 42 (17.50) 0.2428c 10 (29.41) 37 (17.79) 0.1576d
Anti-dyslipidemic
drugs
n (%) 4 (11.43) 33 (13.75) 1.0000d 3 (8.82) 12 (5.77) 0.4496d
Anti-diabetic drugs
n (%) 6 (17.14) 31 (12.92) 0.4388d 6 (17.65) 22 (10.58) 0.2477d
SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST aspartate aminotransferase, UA uric acid, RBC red
blood cell count, WBC white blood cell count, MCH mean corpuscular hemoglobin, PLT platelet count, MPV mean platelet volume, PDW
platelet distribution width, HGB hemoglobin, LDL-C low-density lipoprotein cholesterol
a The result of student’s t test
b The result of Wilcoxon rank sum test
c The result of v2 test
d The result of Fisher’s exact test
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300 and its individual components [36]. In this study, WBC
301 was found to be associated with MetS in 20–35-year-old
302 and 36–50-year-old groups for males and females. It is
303 indicated that WBC is strongly associated with MetS for
304 young adults. In this study, young adults have higher
305 prevalence of elevated TG, reduced HDL-C, and obesity
306 than elderly people.
307 Several studies showed that both obesity and dyslipi-
308 demia were the major precursors for development of MetS,
309 and perivascular white adipose tissue can release proin-
310 flammatory cytokines [37, 38], such as IL-8, leading to
311 elevated WBC, especially the monocytes and granulocytes.
312 In addition, TNF-a is shown to be constitutively expressed
313 by adipose tissue, and this proinflammatory cytokines
314 leads to elevated WBC [39, 40]. Therefore, the total WBC
315 was positively associated with MetS. And many studies
316 have shown the similar results. One study conducted on a
317 Japanese population showed that the correlation between
318 WC and CRP was significantly stronger in younger men
319 than in older men [36]. And, another study displayed a
320 correlation between serum CRP and WBC and some CVD
321 risk factors among young adults [41]. Significant correla-
322 tion of CRP with BMI and WC was discovered in ado-
323 lescents and young adults in one study conducted in Asian
324 Indians [42].
325 RBC counts and HGB were associated with MetS and its
326 components in men and women [43]. Our results showed
327that HGB was positively associated with MetS for 36–50-
328year-old male subjects and 51–65-year-old female subjects.
329Neutrophil counts were significantly increased in MetS
330[44]. In this study, significant association between neutro-
331phil counts and the incidence of MetS was found in 20–35-
332year-old female subjects.
333Park et al. [45] reported that PLT and MPV might be a
334surrogate marker associated with clustered MetS in
335women. PLT counts may be a potential marker associated
336with MetS components [17], and our results showed the
337same association between PLT and MetS for 36–50-year-
338old female subjects.
339Subjects with MetS had elevated levels of oxidized LDL
340[46]. Circulating oxidized LDL seems to express the level
341of oxidative stress and associate with the risk factors of
342MetS [47]. A strongly positive association between LDL-C
343and MetS was found for 51–65-year-old male and female
344subjects. It indicates that LDL-C is strongly associated with
345MetS for elderly people.
346Although several reports have demonstrated that there is
347a close relationship between RBC, MPV, and MetS [48–
34850], no positive associations between these hematological
349parameters and MetS were found in our study.
350There were some limitations to this study. First, hema-
351tological parameters were assessed from a single blood
352sample in the study, and therefore intra-individual variation
353cannot be taken into account. Second, information about
Table 5 Associated risk factors of MetS by gender and age
Gender Age at inclusion Parameter Estimate Standard error P value OR 95 % CI for OR
Lower Upper
Male 20–35 ALT 0.733 0.213 0.0006 2.080 1.371 3.159
UA 0.758 0.326 0.0004 2.135 1.294 3.614
WBC 0.393 0.154 0.0071 1.482 1.169 2.974
36–50 ALT 0.884 0.306 0.0039 2.421 1.335 3.412
WBC 0.699 0.208 0.0021 2.012 1.290 4.010
HGB 0.044 0.018 0.0480 1.045 1.018 2.020
51–65 ALT 1.451 0.664 0.0289 4.267 1.161 6.781
LDL-C 1.124 0.584 0.0176 3.078 2.468 5.131
Female 20–35 neutrophil 0.349 0.169 0.0356 1.059 1.023 1.453
WBC 0.335 0.116 0.0124 1.398 1.145 3.011
UA 0.421 0.211 0.0341 1.523 1.040 3.147
36–50 WBC 1.224 0.642 0.0038 3.400 1.818 4.528
PLT 0.962 0.697 0.0133 2.616 1.432 3.033
51–65 UA 0.005 0.003 0.0298 1.025 1.011 1.321
HGB 0.228 0.012 0.0164 1.256 1.145 3.105
LDL-C 0.761 0.247 0.0231 2.140 1.524 4.359
Model was adjusted for the presence of anti-hypertensive, anti-dyslipidemic, and anti-diabetic medication use
ALT alanine aminotransferase, UA uric acid, WBC white blood cell count, PLT platelet count, HGB hemoglobin, LDL-C low-density lipoprotein
cholesterol
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354 lifestyles was not available, and the multivariate model was
355 not adjusted for these factors. But the lifestyle variables
356 will be included in further studies. Third, as Beijing Ton-
357 gren Hospital is located in the urban area of Beijing,
358 selection bias may be that there were more people with
359 modern life style recruited for the research. In addition, the
360 study was based on a population attending for routine
361 health check-up from one single hospital. Therefore, the
362 demographics and referral source may limit the general-
363 ization of the results. And further studies using the general
364 population would be desirable.
365Conclusions
366Our study sample showed that the 5-year cumulative
367incidence of MetS was 10.82 %, with 14.22 % of males
368and 7.59 % of females having MetS after 5-year follow-up.
369Among all the hematological parameters, WBC is posi-
370tively associated with MetS for young adults, while LDL-C
371is positively associated with MetS for elderly people. ALT
372is positively associated with MetS for males only. The
373association between WBC, LDL-C, and MetS was age-
374specific. While the association between ALT and MetS was
a Risk factors for 20-35-year-old male subjects
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Fig. 3 OR and 95 % CI for risk factors of MetS. ALT alanine aminotransferase, UA uric acid, WBC white blood cell count, HGB hemoglobin,
LDL-C low-density lipoprotein cholesterol, PLT platelet count, OR odds ratio, CI confidence interval
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375 gender-specific. The study provides further evidence in
376 support of using hematological markers for early detection
377 of different age groups of individuals at risk of MetS.
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